Clinical Trials Logo

Aggressive B-cell Lymphoma clinical trials

View clinical trials related to Aggressive B-cell Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02846935 Completed - T-cell Lymphoma Clinical Trials

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Start date: April 25, 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate how well the study drug works and safety of oral decitabine in patients with refractory or relapsed lymphoid malignancies. The decitabine is being given at a lower dose than used for its approved use. It is also being given with another drug, tetrahydrouridine (THU), to improve the exposure of lymphoma cells to decitabine.